SOLICITATION NOTICE
Q -- Laboratory Support Services related to Circulating Inflammation Markers and Prospective Risk of Noncardia Gastric Cancer
- Notice Date
- 8/29/2016
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP62687-76
- Archive Date
- 9/9/2016
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES. Description: National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Infections and Immunoepidemiology Branch (IIB), plans to procure on a sole source basis laboratory support services to test and analyze using proximity extension assay technology, from Olink AB, Org. No. 556663-6998, Dag Hammarskjölds väg 52B, SE-752 37 Uppsala, SWEDEN. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 621511 and the business size standard is $32.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Its renowned epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division's research impacts public health policy in the United States and around the world. The IIB's research mission is to discover infectious causes of cancer, to elucidate the determinants of malignancy for established oncogenic infections, to uncover novel infection-cancer associations, and to clarify how alterations in immunity and inflammation relate to cancer risk. IIB investigators collaborate with researchers from a variety of disciplines in the U.S. and abroad. In addition to epidemiologic and clinical data, many IIB field studies include an extensive biological specimen collection component that allows for careful molecular testing to better define both exposures and outcomes of interest. The specific aims of this project are to test pre-diagnostic gastric cancer and control samples for a proximity extension assay (Proseek Multiplex inflammation panel) and to compare results with the DCEG Luminex multiple immune panel (MIP). The IIB is currently using the DCEG Multiplex Immune Panel (MIP) by Millipore to evaluate 70 analytes within the Japan Public Health Center (JPHC) Cohort II. To expand this research effort with the JPHC, the IIB will measure additional markers, including important modulators of apoptosis, plasminogen activation, tissue remodeling, and the IL-17 pathway that are not assessed by the current DCEG MIP. This study will provide etiologic insight about carcinogenic pathways and potentially identify predictive marker profiles applicable for risk stratification. Contractor shall perform the following: TECHNICAL REQUIREMENTS: The Contractor will test 600 blood samples for circulating levels of 92 immune-related protein biomarkers using proximity extension assay technology (Proseek Multiplex Inflammation I), and provide complete analysis services per sample. The 92 markers are: 4E-BP1, ADA, ARTN, AXIN1, BDNF, Beta-NGF, CASP-8, CCL4, CCL11, CCL19, CCL20, CCL23, CCL25, CCL28, CD244, CD40, CD5, CD6, CDCP1, CSF-1, CST5, CX3CL1, CXCL1, CXCL5, CXCL6, CXCL9, CXCL10, CXCL11, DNER, EN-RAGE, FGF-19, FGF-21, FGF-23, FGF-5, Flt3L, hGDNF, HGF, IFN-gamma, IL-1 alpha, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-10RA, IL-10RB, IL-12B, IL-13, IL-15RA, IL-17A, IL-17C, IL-18, IL-18R1, IL-2, IL-20, IL-20RA, IL-22 RA1, IL-24, IL-2RB, IL-33, LAP TGF-beta-1, LIF, LIF-R, MCP-1, MCP-2, MCP-3, MCP-4, MIP-1 alpha, MMP-1, MMP-10, NRTN, NT-3, OPG, OSM, PD-L1, SCF, SIRT2, SLAMF1, ST1A1, STAMPB, TGF-alpha, TNF, TNFB, TNFRSF9, TNFSF14, TRAIL, TRANCE, TSLP, TWEAK, uPA, VEGF-A. CONTRACTOR QUALIFICATIONS: The contractor needs to be proficient in multiplex measurement of immune markers using proximity extension assay technology as demonstrated by reputation in the field, scientific reports or other evidence of appropriate knowledge and capacity. REPORTING AND/OR DELIVERABLES: The contractor will provide a comprehensive report via an electronic file (in an accessible format such as xlsx,.dta, or.csv) reporting levels of circulating markers for each sample to the NCI Technical Point of Contact. GOVERNMENT RESPONSIBILITIES: The Government will be responsible for coordinating of transfer of specimens and data under code to maintain blinding of the testing laboratory until the end of the study. PERFORMANCE PERIOD: The Period of Performance shall be twelve (12) months from the effective date of the order. INSPECTION AND ACCEPTANCE: The deliverables defined in section E will be scrutinized and subsequently accepted within 30 days of receipt. The Government will review data for consistency of quality assurance sample measurements prior to final acceptance of delivered data. PAYMENT: Payment shall be made in arrears upon receipt and acceptance of each deliverable. Payment authorization requires submission of an invoice per the Invoice & Payment Provision included in the order. This support services are provided by OLINK AB. The current Government requirement requires the services of Olink AB to provide proximity extension assays for 92 markers mentioned above. Olink's Multiplex Inflammation Panel is a proprietary test to measure these specific markers with minimal cross-reactivity in a single drop of biospecimen. The low volume (10uL per sample) proximity extension assay by Olink (Proseek®) has been selected for use as the IIB only have 50uL of each specimen for this project. In addition, there are at least 20 overlapping markers common to both panels (Proseek and MIP) that will provide confirmation of equivalency between the two platforms. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 4:00PM EDT, on Sept. 8, 2016. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02CP62687-76 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP62687-76/listing.html)
- Record
- SN04245378-W 20160831/160829235347-0c59dd2803408a8dc6fa84f88ce5abf5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |